Tristetraprolin inhibits gastric cancer progression through suppression of IL-33

• DOI: 10.1038/srep24505
• Publication Date: 2016-04-14T12:12:32Z
• Authors: Kaiyuan Deng; Hao Wang; Ting Shan; Yigang Chen; Hong Zhou; Qin Zhao; Jiazeng Xia
• Keywords: Interleukin-33; Survival Analysis; Article; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Tristetraprolin; Cell Movement; Stomach Neoplasms; Cell Line, Tumor; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Cell Proliferation

AbstractTristetraprolin (TTP) is an adenine/uridine (AU)-rich element (ARE)-binding protein that can induce degradation of mRNAs. In this study, we report that TTP suppresses the expression of interleukin-33 (IL-33), a tumor-promoting inflammatory cytokine and thereby inhibits the progression of gastric cancer (GC). Overexpression of TTP decreased the level of IL-33, whereas knockdown of TTP increased IL-33 levels. We also discovered that TTP inhibited the proliferation, migration and invasion of GC cell lines through regulation of IL-33. Furthermore, TTP RNA and protein levels were remarkably reduced in GC and inversely correlated with IL-33 level and they were also closely associated with depth of invasion, lymph node metastasis, advanced TNM stage, as well as survival rate. Taken together, these findings identified TTP as a downregulator of IL-33 and further suggest that TTP can serve as a novel biomarker for the diagnosis of GC and as a potential therapeutic target for GC treatment.